How much does a course of treatment with Veentuzumab/Besifux cost?

Enfortumab is a targeted anti-cancer monoclonal antibody for locally advanced or metastatic urothelial carcinoma (bladder cancer). As a new type of tumor immune-targeted drug, it provides an important treatment option globally for patients who have previously received PD-1/PD-L1 inhibitors and platinum-based chemotherapy. Drug prices are relatively high due to their high-tech R&D costs and precise therapeutic properties.

In overseas markets, the European version of the original drug of veentuzumab has been launched. The specification is 20 mg per box and the price is about more than 7,000 yuan, while the price of 30 mg per box may be as high as more than 10,000 yuan. Price differences are affected by exchange rates, import taxes and regional policies, and may fluctuate during actual purchase. The amount of medication required for a complete course of treatment will vary depending on the patient's weight, dosing period and treatment plan. Usually in a single-drug regimen, patients need to calculate the dose according to body weight per cycle and infuse intravenously on days 1, 8, and 15 of a 28-day cycle; if used in combination with pembrolizumab, the dose should be infused on days 1 and 8 of a 21-day cycle. Calculated in this way, the drug cost for each course of treatment may reach tens of thousands of yuan.

Domestically, the generic drug Vientuzumab for injection has been launched in China, but due to its short time on the market, the specific price and medical insurance policy have not been clearly disclosed. When patients use it in China, they need to purchase it through regular hospital channels and strictly follow the doctor's instructions to ensure drug safety and therapeutic effect. At the same time, patients can pay attention to relevant policy developments. As domestic drug pricing and medical insurance reimbursement policies gradually improve, prices may be adjusted in the future.

In addition to the cost of the drug itself, there may also be related costs such as intravenous infusion, nursing, monitoring and follow-up during the treatment process. Although these costs are not directly included in the drug price, they are also an important part of the overall economic burden of treatment for patients.

Reference: https://www.padcev.com/